Mie University

Otsuka Pharmaceutical Company, Limited

Tetsu Kobayashi

Esteban C Gabazza

Hidekazu Toyobuku

Tetsuya Hasegawa

Ayako Fukuda

Osamu Taguchi

Esteban C Gabazza Gabazza

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Preventive or therapeutic agent for fibrosis

A transgenic non-human mammal has a genome that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a &#x3b2;-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter. The hMMP2 is systemically expressed in the transgenic non-human mammal, which thus provides a suitable animal model for studying chronic obstructive pulmonary disease and related diseases and conditions.

Transgenic non-human mammal that expresses human MMP2

Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1.

Growing community of inventors

Tsu, Japan

Tetsu Kobayashi